anti-Complement Factor C8 β Propeptide, mAb (14A10)

CHF 315.00
In stock
YIF-LF-MA0181100 µlCHF 315.00
More Information
Product Details
Synonyms C8B; Complement Component C8 β Chain; Complement Component 8 Subunit β
Product Type Monoclonal Antibody
Clone 14A10
Isotype Mouse IgG1 κ
Immunogen/Antigen Protein purified from human plasma.

Western Blot (1:2,000)
Immunoprecipitation (1 μl)

Crossreactivity Human
Purity Detail Ammonium sulfate precipitation.
Formulation Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol.
Isotype Negative Control

Mouse IgG1 Isotype Control

Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

Declaration Manufactured by AbFrontier
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF

The complement system is a part of the larger immune system and three biochemical pathways are present: the classical complement pathway, the alternative pathway, and the mannose-binding lectin pathway. Human complement factor C8 is one of five components (C5b, C6, C7, C8, and C9) that interact to form the cytolytic membrane attack complex (MAC) which is the cytolytic end product of the complement cascade. MAC is typically formed on the surface of intruding pathogenic bacterial as a result of the activation of the complement system, and it is one of the ultimate weapons of the immune system. C8 is composed of an α (64 kDa), β (64 kDa), and γ (22 kDa) subunit. Within C8, the subunits are arranged as a disulfide-linked C8 α-γ heterodimer that is noncovalently associated with C8 β. During MAC formation, C8 α mediates binding and self-polymerization of C9 to form a pore-like structure on the membrane of target cells. Constituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells.

Product References

1) Scibek, J.J. et al., (2002) Biochemistry. 41:14546-14551. (General)
2) Esser, A. F., (1994) Toxicology 87:229-247. (General)
3) Muller-Eberhard, H. J., (1988) Annu. ReV. Biochem. 57:321-347. (General)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.